Jaskaran Singh
Research scientist at Janssen Research and Development (Johnson & Johnson Innovative Medicine)
Papers
Trials
Key Impact
He is a key industry researcher on ketamine/esketamine trials for treatment-resistant depression, including pivotal studies that helped characterize antidepressant efficacy, dosing, and dissociation safety.
Background & Research
Jaskaran B. Singh is a pharmaceutical industry researcher whose published work centers on rapid-acting antidepressant treatments, especially ketamine and esketamine, for treatment-resistant depression. A PubMed record for the 2016 randomized ketamine dose-frequency study lists him as the first author and places him at Janssen Research and Development. His later work also appears on analyses of dissociation, adverse events, and antidepressant response in esketamine trials.
Collaboration Network
10 collaborators· click a node to visit their profile
Full network →